메뉴 건너뛰기




Volumn 8, Issue 1, 2015, Pages

AFM13: A first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

Author keywords

[No Author keywords available]

Indexed keywords

AFM 13; AFM13 MONOCLONAL ANTIBODY; BISPECIFIC ANTIBODY; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CD16A ANTIBODY; CD30 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD30 ANTIGEN;

EID: 84938574282     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0188-3     Document Type: Article
Times cited : (88)

References (30)
  • 1
    • 84887942578 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
    • 3843585 24261963
    • Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88.
    • (2013) J Hematol Oncol , vol.6 , Issue.1 , pp. 88
    • Akinleye, A.1    Avvaru, P.2    Furqan, M.3    Song, Y.4    Liu, D.5
  • 2
    • 84883160397 scopus 로고    scopus 로고
    • Ibrutinib and novel BTK inhibitors in clinical development
    • 1:CAS:528:DC%2BC3sXhsVagtrjI 3751776 23958373
    • Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6(1):59.
    • (2013) J Hematol Oncol , vol.6 , Issue.1 , pp. 59
    • Akinleye, A.1    Chen, Y.2    Mukhi, N.3    Song, Y.4    Liu, D.5
  • 3
    • 84876249574 scopus 로고    scopus 로고
    • MEK and the inhibitors: From bench to bedside
    • 1:CAS:528:DC%2BC3sXmvFejurg%3D 3626705 23587417
    • Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):27.
    • (2013) J Hematol Oncol , vol.6 , Issue.1 , pp. 27
    • Akinleye, A.1    Furqan, M.2    Mukhi, N.3    Ravella, P.4    Liu, D.5
  • 5
    • 85064289101 scopus 로고    scopus 로고
    • Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
    • Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res. 2013;1(1):5.
    • (2013) Biomarker Res , vol.1 , Issue.1 , pp. 5
    • Furqan, M.1    Mukhi, N.2    Lee, B.3    Liu, D.4
  • 6
    • 84876953788 scopus 로고    scopus 로고
    • B-Raf and the inhibitors: From bench to bedside
    • 1:CAS:528:DC%2BC3sXotFWrsLw%3D 3646677 23617957
    • Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):30.
    • (2013) J Hematol Oncol , vol.6 , Issue.1 , pp. 30
    • Huang, T.1    Karsy, M.2    Zhuge, J.3    Zhong, M.4    Liu, D.5
  • 7
    • 84875359668 scopus 로고    scopus 로고
    • Targeting p53 by small molecules in hematological malignancies
    • 1:CAS:528:DC%2BC3sXmsFGmsLY%3D 3614876 23531342
    • Saha M, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6(1):23.
    • (2013) J Hematol Oncol , vol.6 , Issue.1 , pp. 23
    • Saha, M.1    Qiu, L.2    Chang, H.3
  • 13
    • 84884698526 scopus 로고    scopus 로고
    • The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
    • 3851976 24283718
    • Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6(1):74.
    • (2013) J Hematol Oncol , vol.6 , Issue.1 , pp. 74
    • Shi, L.1    Chen, S.2    Yang, L.3    Li, Y.4
  • 17
    • 84927150740 scopus 로고    scopus 로고
    • Immune checkpoint blockade in cancer therapy
    • 25605845
    • Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974-82.
    • (2015) J Clin Oncol , vol.33 , Issue.17 , pp. 1974-1982
    • Postow, M.A.1    Callahan, M.K.2    Wolchok, J.D.3
  • 18
    • 84879813079 scopus 로고    scopus 로고
    • Chimeric antigen receptor-engineered T cells for cancer immunotherapy: Progress and challenges
    • 1:CAS:528:DC%2BC3sXht1ajurvF 3706354 23829929
    • Han E, Li X-l, Wang C-R, Li T-F, Han S-Y. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 2013;6(1):47.
    • (2013) J Hematol Oncol , vol.6 , Issue.1 , pp. 47
    • Han, E.1    Li, X.-L.2    Wang, C.-R.3    Li, T.-F.4    Han, S.-Y.5
  • 23
    • 0033545963 scopus 로고    scopus 로고
    • Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity
    • 1:CAS:528:DyaK1MXjtFCntL4%3D 21913 10318937
    • Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A. 1999;96(10):5640-4.
    • (1999) Proc Natl Acad Sci U S A , vol.96 , Issue.10 , pp. 5640-5644
    • Mandelboim, O.1    Malik, P.2    Davis, D.M.3    Jo, C.H.4    Boyson, J.E.5    Strominger, J.L.6
  • 24
    • 0027358685 scopus 로고
    • A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo
    • 1:CAS:528:DyaK2cXhtlWrsLY%3D 8244580
    • Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, et al. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer. 1993;55(5):830-6.
    • (1993) Int J Cancer , vol.55 , Issue.5 , pp. 830-836
    • Hombach, A.1    Jung, W.2    Pohl, C.3    Renner, C.4    Sahin, U.5    Schmits, R.6    Wolf, J.7    Kapp, U.8    Diehl, V.9    Pfreundschuh, M.10
  • 28
    • 0027197493 scopus 로고
    • "Diabodies": Small bivalent and bispecific antibody fragments
    • 1:CAS:528:DyaK3sXltlOjur8%3D 46948 8341653
    • Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993;90(14):6444-8.
    • (1993) Proc Natl Acad Sci U S A , vol.90 , Issue.14 , pp. 6444-6448
    • Holliger, P.1    Prospero, T.2    Winter, G.3
  • 29
    • 84938628792 scopus 로고    scopus 로고
    • Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    • in press
    • Wu J, J Fu, M Zhang, Liu D: Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol 2015, 8:in press.
    • (2015) J Hematol Oncol , vol.8
    • Wu, J.1    Fu, J.2    Zhang, M.3    Liu, D.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.